{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:41:07Z","timestamp":1782981667119,"version":"3.54.5"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ground-glass nodules (GGNs) are generally considered an early stage of lung cancer. The imaging characteristics and curative efficacy of multiple GGNs as metastases remain unclear. Microsatellite instability-high (MSI-H) is a biomarker for immunotherapy. The therapeutic effect and prognosis for patients with MSI-H and Epidermal Growth Factor Receptor (EGFR)-sensitive mutation stays uncertain. Here, we report a case of a lung adenocarcinoma patient presenting with ground-glass metastases, MSI-H, and EGFR-sensitive mutation and provide clinical data on the efficacy and prognosis. We describe the predictive significance of carcinoembryonic antigen (CEA) for disease progression when there is inconsistency between treatment effectiveness and CEA changes.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1478205","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T04:31:03Z","timestamp":1730089863000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report: MSI-H, EGFR mutation, and ground-glass nodules as diffuse pulmonary hematogenous metastases"],"prefix":"10.3389","volume":"15","author":[{"given":"Liuer","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"107255","DOI":"10.1016\/j.lungcan.2023.107255","article-title":"Genomic characteristics and prognosis of lung cancer patients with MSI-H: A cohort study","volume":"181","author":"Tian","year":"2023","journal-title":"Lung Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1088683","article-title":"Long-term benefit of immunotherapy in a patient with squamous lung cancer exhibiting mismatch repair deficient\/high microsatellite instability\/high tumor mutational burden: A case report and literature review","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ccell.2018.06.006","article-title":"Epidermal growth factor receptor extracellular domain mutations in glioblastoma present opportunities for clinical imaging and therapeutic development","volume":"34","author":"Binder","year":"2018","journal-title":"Cancer Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013809","article-title":"Nonsmall cell lung cancer with rare exon 7 p.A289V mutation in the EGFR gene responds to Icotinib treatment: A case report","volume":"97","author":"Dai","year":"2018","journal-title":"Med (Baltimore)"},{"key":"B5","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/annonc\/mdy554","article-title":"Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS","volume":"30","author":"Wu","year":"2019","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.13.12088","article-title":"Aerogenous metastases: a potential game changer in the diagnosis and management of primary lung adenocarcinoma","volume":"203","author":"Gaikwad","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12405","article-title":"Case report: CEA elevation can be a marker of increased inflammation during treatment with oxaliplatin","volume":"38","author":"Kerr","year":"2018","journal-title":"Anticancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.2003.012963","article-title":"Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours","volume":"57","author":"Jubb","year":"2004","journal-title":"J Clin Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1266304","article-title":"Case report: Target and immunotherapy of a lung adenocarcinoma with enteric differentiation, EGFR mutation, and high microsatellite instability","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-015-1892-7","article-title":"Microsatellite instability in pulmonary adenocarcinomas: a comprehensive study of 480 cases","volume":"468","author":"Warth","year":"2016","journal-title":"Virchows Arch"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.02.011","article-title":"Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma","volume":"17","author":"Vokes","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030841","article-title":"Osimertinib resistance: molecular mechanisms and emerging treatment options","volume":"15","author":"Gomatou","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1478205\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T04:31:05Z","timestamp":1730089865000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1478205\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2024.1478205"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1478205","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"article-number":"1478205"}}